SESSION 1: PERSONALIZED MEDICINE – THE FUTURE OF DRUG DEVELOPMENT
- Academic perspective on enabling precision immuno-oncology – Zlatko Trajanoski (Medical University of Innsbruck, Austria)
- Industry perspective: the challenges & opportunities of personalized/stratified medicine from a development and patient access perspective – Michael Zaiac (Novartis, Switzerland)
- Biotech perspective – Kieran O’Kane (Biodesix, United States)
- Role of in vitro diagnostics in the authorization of anticancer medicines – Harald Enzmann (bFarm, Germany)
- Payer’s perspective – Anouk Waeytens (RIZIV / INAMI, Belgium)
- Patient advocate’s perspective – Francesco De Lorenzo (ECPC)
SESSION 2: CHALLENGES FOR ACCESS TO BIOMARKERS
- Case stories
- David Browning (Oxford Cancer Biomarkers, United Kingdom)
- Kieran O’Kane (Biodesix, United States)
- HTA perspective – Sonia Garcia Perez (AEMPS, Spain)
- Patient advocate’s perspective – Kathi Apostolidis (ECPC, Greece)
- Regulatory point of view: Industry perspective – Claudia Dollins (Merck, Germany)
- Personalised cancer care: translating promise into practice – with multi-stakeholder approach – Titta Rosvall-Puplett (Bristol-Myers Squibb, Belgium)
SESSION 3: THE WAY FORWARD
- Strategies to allow indication based payment for biomarkers – Afschin Gandjour (Frankfurt school of Finance & Management, Germany)
- Developing practical guidance for Member States on implementing precision genomics in medical care – Marc Van den Bulcke (Sciensano, Belgium)
- Access to biomarkers: “Are we ready for value-based precision medicine?” – Patricia Carrigan (Bayer, Germany)
- Payer’s perspective: sustainability of healthcare systems – Annie Pannelay (United Kingdom)
- Potential of real world evidence for access to biomarkers – Jesús María Hernández Rivas (HARMONY/ IBSAL, Spain)
SESSION 4: NEXT STEPS
- The provider’s point of view – Santiago Valor (Labco, Spain)
- Multi-stakeholder approaches for addressing barriers to precision medicine: Diagnostic Quality Assurance pilot – Lindee Goh (Tapestry, United States)